Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
Transcriptomic analysis of extracellular vesicles in the search for novel plasma and thrombus biomarkers of ischemic stroke etiologies
Accurate etiologic diagnosis provides an appropriate secondary prevention and better
prognosis in ischemic stroke (IS) patients; still, 45% of IS are cryptogenic, urging us to enhance
diagnostic precision. We have studied the transcriptomic content of plasma extracellular vesicles
(EVs) (n = 21) to identify potential biomarkers of IS etiologies. The proteins encoded by the selected
genes were measured in the sera of IS patients (n = 114) and in hypertensive patients with (n = 78)
and without atrial fibrillation (AF) (n = 20). IGFBP-2, the most promising candidate, was studied
using immunohistochemistry in the IS thrombi (n = 23) and atrium of AF patients (n = 13). In vitro,
the IGFBP-2 blockade was analyzed using thromboelastometry and endothelial cell cultures. We
identified 745 differentially expressed genes among EVs of cardioembolic, atherothrombotic, and
ESUS groups. From these, IGFBP-2 (cutoff > 247.6 ng/mL) emerged as a potential circulating
biomarker of embolic IS [OR = 8.70 (1.84–41.13) p = 0.003], which was increased in patients with
AF vs. controls (p < 0.001) and was augmented in cardioembolic vs. atherothrombotic thrombi
(p < 0.01). Ex vivo, the blockage of IGFBP-2 reduced clot firmness (p < 0.01) and lysis time (p < 0.001)
and in vitro, diminished endothelial permeability (p < 0.05) and transmigration (p = 0.06). IGFBP-2
could be a biomarker of embolic IS and a new therapeutic target involved in clot formation and
endothelial dysfunction., This research was funded by Instituto de Salud Carlos III, ISCIII (PI22/00436, PI21/00946
and PI20/01319) and co-funded by the European Regional Development Fund, ERDF, “A way to
make Europe”; CIBERCV (CB16/11/00483); RICORS-ICTUS (RD21/0006/0008), Government of
Navarra (MINERVA II) and Virto S.A.